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Abstract
The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1
has generated considerable excitement and emboldened efforts to build on this important foundation. Research
efforts are now focused on understanding the mechanism of action of these immunotherapies, identifying new
inhibitory mechanisms that could be targeted to achieve responses in patients with refractory cancers, and
developing approaches that might exhibit efficacy against “immunologically inert” tumors. The outstanding
challenges in moving forward are developing reliable strategies for determining which patients will respond
optimally to a given immunotherapy, and what combination of immunotherapies and conventional therapies will
prove beneficial against each tumor type. These issues were discussed in a one-day workshop at the SITC
meeting in November 2014.
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Beyond the inflamed/non-inflamed classification
of the immune microenvironment
This session highlighted new immune-based approaches
to classify tumors with the aim of improving prognostic
power. Jerome Galon (INSERM, France) presented the
Immunoscore, an immune-profiling approach that uses
four parameters to determine an immune contexture for
a given tumor sample. The four parameters account for
T cell type (CD8) and function (the CD45RO memory
marker), cell density, and location (invasive margin or
center) of the immune cells within tumor tissue. Immu-
noscore data collected thus far indicate that a high
immunoscore correlates strongly with better prognosis.
Immunoscore profiling has been validated initially in
colorectal carcinoma and currently a worldwide task
force is investigating its application to many other can-
cer types. Toni Ribas (UCLA, USA) presented data
showing the application of components of immunoscore
profiling to melanoma. Scoring for the presence of CD8,
CD4, PD-1 and PD-L1 among responders and non-
responders to checkpoint blockade therapy showed that
the best predictors of response were the presence of
CD8+ T cells in the invasive margin and expression of PD-
1 and PD-L1. Suzanne Topalian (Johns Hopkins, USA)
expanded on the theme of PD-1/PD-L1 expression as a
predictor of response. She pointed out that despite the use
of various antibodies in different studies, all have shown
that a patient is 2–3 times more likely to respond if pre-
treatment biopsies exhibit PD-L1 expression. Interestingly,
PD-L1 expression is often observed at the tumor margin
as if providing a “shield” to disarm infiltrating T lympho-
cytes. However, she also emphasized that not all patients
that responded well to PD1/PD-L1 targeted therapy had
PD-L1+ biopsies. She presented data showing that PD-L1
expression may vary among melanoma lesions from the
individual patient or may be present at focal sites of tumor
lesions, raising the possibility that some PD-L1+ tumors/
patients may be missed due to sampling error. Therefore,
using PD-L1 expression as a “biomarker” to select patients
for anti-PD-1 therapy may result in exclusion of patients
that would benefit from therapy. In some patients receiv-
ing combined anti-CTLA-4 and PD-1, it has been noted
that therapy can drive T cells to the tumor site and in-
crease T cell production of IFN-γ which in turn can in-
duce PD-L1 expression by tumor cells. Thus, T cell
infiltration and PD-L1 expression within tumor tissue can
be dynamic and other markers are needed to select pa-
tients for therapies.
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What does an “immunologically inert” tumor
mean?
This session highlighted approaches to treating tumors
that lack a T cell infiltrate. This could be due to a lack of
recognizable tumor antigens. Previously, the most suc-
cessful immunotherapies have utilized checkpoint block-
ade; however, immunologically inert tumors are resistant
to this therapy. Bob Schreiber (Washington University,
USA) emphasized the importance of identifying mutant
antigens in edited versus non-edited tumors. He pre-
sented data on the use of exome sequencing to identify
tumor antigens that have or have not undergone immu-
noediting. By comparing mutant proteins of unedited re-
gressor tumors to those from edited progressor tumors,
personalized cancer vaccines have been developed that
trigger T cell responses against tumor-specific mutant
antigens and showed that these therapies are as effective
as checkpoint receptor blockade. These mutant antigens
can indeed alter the immunogenicity of the tumor, such
as the R913L mutant Spectrin-β2, which drastically in-
creases the immunogenicity of d42m1 sarcoma. Tom
Gajewski (University of Chicago, USA) presented re-
search on determining better targets for non-infiltrated
tumors through innate immune sensing, allowing for
better priming of the adaptive immune response. His la-
boratory identified that STING, an intracellular mem-
brane tethered protein, could be a potential therapeutic
target for immunologically inert tumors. The STING
pathway triggers immune responses via a tumor cell:DC
interaction and pre-clinical studies showed that STING
agonists greatly reduce tumor growth. Gajewski also
mentioned the importance of β-catenin signaling. When
this pathway is active, T cells are excluded, altering the
microenvironment. Previous work has shown that cell
death in the tumor microenvironment can also be a crit-
ical component of activating the innate immune re-
sponse through the release of endogenous adjuvants or
defensins. Michael Lotze (University of Pittsburgh, USA)
stressed that an important factor to take into account in
treating tumors that have developed resistance to cyto-
toxic chemotherapies is cancer cell death. The tumor
microenvironment is highly hypoxic and this can lead to
altered expression of autophagy molecules, such as
HMGB1. Therefore, modulation of HMGB1-driven au-
tophagy and DAMP release may be a strategy for im-
proving responses to chemo-resistant tumors. Jennifer
Wargo (MD Anderson Cancer Center, USA) presented
data showing that by combining novel targeted therapies
with more classical ones, such as BRAF inhibitors, mela-
nomas can actually become more immunogenic through
enhanced expression of tumor antigens and tumor cell
death. With this theme in mind, Jennifer Wargo and col-
leagues combined targeted therapy with immunotherapy
and found that the combination of BRAF inhibitors and
anti-PD-1 led to a reduction in melanoma growth, as
well as an increase in CD8+ effector T cells in the tumor
microenvironment. Positive responses were also shown
in other murine tumor models, such as Gastrointestinal
Stromal Tumor (GIST). Clinical trials are currently un-
derway utilizing this approach.
How to break tumor-induced immune suppression
This session highlighted mechanisms of immune suppres-
sion in tumors and strategies for targeting them. Dario
Vignali (University of Pittsburgh, USA) discussed the role
of regulatory T cells (Tregs). He showed a striking reduc-
tion in tumor growth by decreasing Treg stability and
function through genetic deletion or blockade of the sur-
face receptor, Neuropilin-1 (Nrp1), while maintaining im-
mune homeostasis. Indeed, mice lacking Nrp1 on their
Tregs survive long term without inducing systemic auto-
immune inflammatory reactions. He showed that targeting
the Treg-derived inhibitory cytokine interleukin-35 (IL35)
also limited tumor growth. Ana Anderson (Harvard Med-
ical School, USA) presented data on TIGIT, a novel check-
point receptor that binds to nectin and nectin-like ligands,
and its role in regulating anti-tumor responses. She
showed that TIGIT restrains anti-tumor CD8+ T cell re-
sponses and could be a promising target for combinatorial
blockade together with Tim-3. She emphasized that as the
number of checkpoint receptors grows, it is critical to
achieve a greater understanding of the unique function of
each checkpoint receptor in order to inform the rational
application of combinatorial immunotherapy approaches.
Susan Kaech (Yale School of Medicine, USA) presented
data that BRAF inhibitors can trigger immune response
by increasing IFN-γ production and CD40L expression by
T cells and consequently activating macrophages within
the tumor. While this is advantageous, BRAF inhibitors
also caused an increase in PD-1 expression, emphasizing
the requirement for combinatorial approaches. John
Wherry also focused on the importance of combinatorial
approaches. He pointed out that CD8+ T cells within the
tumor can be divided into two major subpopulations:
EomesHiPD-1Hi, and TbetHiPD-1Lo. He underscored that
the changes in the EomesHiPD-1Hi subset could be useful
in predicting the response to immunotherapy in combin-
ation with radiation. He emphasized that while these cells
are considered “exhausted”, they retain some function and
could contribute to control of tumor growth. He also
pointed out that PD-1 knockout cells can still express high
levels of other checkpoint inhibitors which underlines the
potential benefit of combination immunotherapy.
Ideas for innovative combination approaches in
the future
This session focused on novel combinatorial approaches
in the clinic. Hassane Zarour (University of Pittsburgh,
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USA) highlighted Tim-3 and BTLA as potential partners
for anti-PD-1 therapy. He also stressed the potential util-
ity of anti-IL-10 therapy as he showed that CD8+ T cells
increased IL-10 receptor expression after PD-1 blockade.
Steve Hodi (Dana-Farber Cancer Institute, USA) pre-
sented data combining anti-CTLA-4 with cytokines,
such as GM-CSF, or anti-angiogenesis treatments, such as
VEGF blockade. He underscored the importance of un-
derstanding the mechanisms induced by these combined
therapies may allow for improvement in efficacy. Mario
Sznol (Yale Cancer Center, USA) gave a provocative talk
in which he referred to immunotherapy as “imprecision
medicine”. He cited all the ongoing permutations of im-
munotherapy approaches in the clinic and how little we
actually know about how any of these work.
Conclusions
While promising immunotherapies are now in the clinic
with an encouraging pipeline of new targets under devel-
opment, considerable work lies ahead in order to deter-
mine the most effective therapeutic combinations for each
tumor type and individual patients. In this workshop, the
potential advantages and challenges of combination im-
munotherapy in pre-clinical models and clinical trails was
evaluated. The enhanced therapeutic effects of combining
anti-CTLA-4 and anti-PD-1 in clinical studies have rein-
forced the value and importance of continued develop-
ment of new immunotherapies against other inhibitory
molecules and testing additional combinatorial ap-
proaches. It is also critical to understand the mechanisms
induced by each immunotherapy or combination of ther-
apies in order to identify potential biomarkers and deter-
mine how to optimize therapies. Lastly, in order to
increase the response rate to immunologically inert tu-
mors, it is important to understand and take advantage of
the mechanisms that drive immune cell infiltration into
the tumor. Such data will be critical to the rational devel-
opment of combinatorial immunotherapies in the future.
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